Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Receives $24.15 Average Price Target from Brokerages

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) has earned a consensus recommendation of “Moderate Buy” from the sixteen analysts that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, fourteen have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $24.1538.

CMPS has been the topic of a number of research analyst reports. Wolfe Research restated an “outperform” rating on shares of Compass Pathways in a research note on Tuesday, July 7th. Royal Bank Of Canada raised their target price on shares of Compass Pathways from $21.00 to $22.00 and gave the company an “outperform” rating in a research report on Thursday, May 14th. Raymond James Financial reiterated a “buy” rating on shares of Compass Pathways in a report on Friday, May 22nd. Canaccord Genuity Group upped their target price on Compass Pathways from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Friday, June 26th. Finally, BTIG Research lifted their price target on Compass Pathways from $14.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday, July 7th.

Institutional Investors Weigh In On Compass Pathways

A number of institutional investors have recently added to or reduced their stakes in CMPS. EverSource Wealth Advisors LLC grew its stake in Compass Pathways by 67.7% in the 1st quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock valued at $26,000 after buying an additional 1,920 shares in the last quarter. Persistent Asset Partners Ltd bought a new position in shares of Compass Pathways in the fourth quarter worth $38,000. Parallel Advisors LLC boosted its holdings in shares of Compass Pathways by 8,450.6% in the first quarter. Parallel Advisors LLC now owns 7,268 shares of the company’s stock worth $40,000 after acquiring an additional 7,183 shares during the period. Advisory Services Network LLC purchased a new position in shares of Compass Pathways in the third quarter valued at $41,000. Finally, North Star Investment Management Corp. grew its position in shares of Compass Pathways by 1,354.0% in the first quarter. North Star Investment Management Corp. now owns 7,517 shares of the company’s stock valued at $42,000 after purchasing an additional 7,000 shares in the last quarter. 46.19% of the stock is owned by institutional investors.

Compass Pathways Stock Performance

Shares of NASDAQ CMPS opened at $11.67 on Friday. The company has a current ratio of 3.32, a quick ratio of 3.32 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $1.57 billion, a P/E ratio of -3.70 and a beta of 2.47. Compass Pathways has a 12 month low of $3.92 and a 12 month high of $15.40. The stock has a 50 day moving average of $12.39 and a 200-day moving average of $8.89.

Compass Pathways (NASDAQ:CMPS) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.15. As a group, equities research analysts predict that Compass Pathways will post -1.24 EPS for the current year.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.